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A retrospective observational study of the effectiveness of
paliperidone palmitate on acute inpatient hospitalization
rates
Daniel Bressingtona,c, Jon Stockb, Sabina Hulbertc and Douglas MacInnesc
This retrospective mirror-image observational study aimed
to establish the effects of the long-acting antipsychotic
injection paliperidone palmitate (PP) on acute inpatient
hospitalization rates. We utilized routinely collected clinical
data to compare the number and length of acute patient
admissions 1 year before and 1 year after initiation of PP.
A single cohort of 66 patients with a diagnosis of
schizophrenia and who had received monthly injections of
PP for at least 1 year were included in the analysis. The
mean number of acute inpatient admissions fell from 0.86 in
the year before PP initiation to 0.23 in the following year
(P= 0.001), and there was a numerical but nonsignificant
decrease in the number of bed days from 32.48 to 31.22
over the study duration. The median number of bed days in
the year before PP initiation was 20, and in the year after
initiation it was 0. The median number of admissions also
fell from 1 to 0 during the same period. The results of the
study should be treated cautiously because of the
limitations of the study design but suggest that patients
with a diagnosis of schizophrenia who continue treatment
with PP over 12 months experience a significant reduction
in hospital admissions compared with the previous year. Int
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Introduction
Schizophrenia is a severe mental illness that often
requires treatment with antipsychotic medication for long
periods to minimize the distress associated with symp-
toms and reduce the likelihood of relapse (Jablensky
et al., 1992; Ascher-Svanum et al., 2006). Increases in the
number of relapses and subsequent hospitalizations are
closely associated with worse long-term patient outcomes
(Falkai et al., 2006) and increased healthcare costs (Polsky
et al., 2006). Because of these negative outcomes, relapse
prevention is a key therapeutic aim in the treatment of
schizophrenia, and antipsychotic medication plays a
significant role (Olivares et al., 2013). Although anti-
psychotic medications can improve symptoms, patient
nonadherence with oral formulations of antipsychotics is
very common and this is associated with a much higher
chance of relapse (Byerly et al., 2007). Some studies have
shown that, compared with oral medication, the use of
long-acting typical and atypical antipsychotic injections
can improve treatment adherence and potentially reduce
readmission rates over the longer term (Edwards et al.,
2005; Haddad et al., 2009).
Numerous long-acting atypical antipsychotic injections
are now available for use, but evidence on their effec-
tiveness in terms of reducing the number and length of
hospitalization is somewhat mixed. Within some pro-
spective observational studies, atypical long-acting
injections have been shown to reduce relapse rates and
readmissions to hospital when compared with oral anti-
psychotics (Chue et al., 2005; Olivares et al., 2009),
whereas some longer-term controlled studies show no
benefit of long-acting atypical injections over oral medi-
cations (Macfadden et al., 2010; Rosenheck et al., 2011).
Different observational studies exploring the effective-
ness of the same atypical antipsychotic drug have also
produced some equivocal findings. For example, a
number of studies have measured the impact of long-
acting risperidone injections on patient hospitalization
rates; some of these studies have shown that it is effective
in reducing inpatient stays (Taylor et al., 2008), whereas
others show an increase in the number of admission days
after initiation (Young and Taylor, 2006; Taylor and
Cornelius, 2010).
Long-acting paliperidone palmitate (PP) injection is an
atypical antipsychotic licensed for the treatment of schi-
zophrenia, and as its availability is relatively recent there
are few studies that explore its effectiveness. PP has been
licensed for use in the UK since early 2011 and has been
used in our clinical setting since June 2011. Clinical trials
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have demonstrated the efficacy of PP in controlled research
studies (Bishara and Taylor, 2008), and a naturalistic
observational cohort study suggests that PP was relatively
well tolerated by patients, with 65% of 200 patients
still receiving the drug after 1 year (Attard et al., 2013).
Only limited information is published about PP’s effec-
tiveness in reducing the length and number of hospital
admissions in real-life clinical practice. One such study
conducted by Taylor and Olofinjana (2014) recently
demonstrated through a 12-month prospective, non-
interventional, observational study that the use of PP
resulted in significant reductions in the number and length
of hospital admissions per patient per year.
Taylor and Olofinjana (2014) study was conducted within
an NHS Trust that provided mental health (MH) services
to patients with a different ethnic demographic profile
(compared with our patient population) and who were
primarily residing in an inner city area; because of this the
results are not directly generalizable to our more rural/
suburban clinical setting. Therefore, the current study
aims to establish the potential effects of PP treatment in
terms of effects on acute inpatient hospitalization rates in
our MH trust.
Methods
The study was carried out in one NHS MH trust located
in southern England and was approved by the Trusts’
clinical audit and effectiveness office as a service eva-
luation on 9 September 2014. All data were anonymized
and held securely in line with the Trust’s data protection
policies.
Key inclusion criteria
We screened the electronic records of male and female
patients with a diagnosis of schizophrenia, aged
18–65 years, who had been treated with PP in both acute
inpatient and outpatient settings. Patients with a mini-
mum of 1 year’s clinical data recorded before initiation of
PP on the electronic patients’ record system and with a
minimum of 1 year’s clinical data recorded after initiation
of PP were included in the analysis. Patients were
included only if they had completed at least 12 months of
treatment with PP. Patients’ data were also excluded if
PP had been used out-of-license or if patients had been
switched from clozapine to PP (as PP is not indicated for
patients who are treatment resistant).
Data collection
The number of acute inpatient admissions and number
of associated bed days in the 1 year before and 1 year
after PP initiation were obtained from patients’ records.
We also gathered a range of other clinical and demo-
graphic data that were recorded in the patients’ electronic
notes, including sex, ethnicity, age at initiation of PP,
employment status, marital status, treatment setting,
duration of contact with MH services, and responsiveness
to PP treatment (as defined by HoNOS scores; Wing
et al., 1998). We wanted to focus on the use of acute
inpatient services and therefore excluded all hospital
admissions and related bed days that related to either
forensic or specialist rehabilitation settings both before
and after PP initiation. Our clinical rationale for excluding
these admissions was that the length of hospitalization
and criteria for patient discharge were more likely to be
related to court restrictions and the need for ongoing
rehabilitation than the effects of antipsychotic treatment.
Primary (a-priori) analysis approach
The primary endpoint for this study was the mean
number of hospital admissions and number of bed days
1 year preceding the initiation of PP and mean number of
hospital admissions and number of bed days in the 1 year
following initiation of PP. Whether the patient was
initiated in the community or in the hospital setting, the
mirror date was set at 2 weeks after PP initiation (Fig. 1).
We chose 14 days as our mirror point in an attempt to
account for the bed days that may be associated with
efficacy failure of the previous drug. This is an important
consideration because it is estimated that 58% of costs
incurred during the first week on a new antipsychotic are
most likely due to treatment ineffectiveness of the pre-
vious antipsychotic rather than failure of the newly
introduced medication (Faries et al., 2009). Our strategy
was based on reports that generally a satisfactory ther-
apeutic response to antipsychotics is usually seen within
2 weeks of initiation (Leucht et al., 2005; Glick et al.,
2009) and that on average PP reaches peak plasma con-
centration around 13 days after the first injection into the
deltoid muscle (Sheehan et al., 2012).
Post-hoc sensitivity analyses
For reasons of transparency and comparability with pre-
viously published similar studies we also adopted an
additional post-hoc sensitivity analysis strategy that was
the same as that described by Taylor and Olofinjana
(2014). In this secondary analysis we used the date of PP
initiation as the mirror point for all outpatients, but for
patients who started on PP as an inpatient we compared
the mean hospitalizations rates before PP with the mean
number in the year following discharge from the index
admission (effectively discounting bed days from the
post-PP calculation where they were part of the index
admission; see Fig. 2).
Data analysis strategy
Data were analyzed using the IBM SPSS statistical
package, version 21 (IBM Corp., 2012). The distribution
of numbers of admissions and bed days was non-normal,
as shown by the histograms and normal Q-Q plot. This
was additionally confirmed by the skewness and kurtosis
indices of the variables, as well as the corresponding
Kolmogorov–Smirnov and Shapiro–Wilk tests of nor-
mality. We therefore used Wilcoxon signed rank tests
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and bootstrap paired sample t-tests to test the null
hypothesis of no difference in number of admissions and
bed days before and after PP initiation.
Results
Data were initially retrieved from 148 patients. After
applying our inclusion criteria a final sample of 66
patients was retained. The main reasons for excluding
cases were related to not having a minimum of 1 year pre-
PP initiation data and having insufficient post-PP initia-
tion data or absence of a diagnosis of schizophrenia. All
PP discontinuers were excluded from the analysis in line
with the study inclusion criteria. We initially intended to
explore responsiveness to PP treatment (as defined by
routinely recorded HoNOS scores), but unfortunately
because of sparseness of data and the irregularity in
which scores were recorded we were left with only nine
patients’ data for analysis and therefore had to abandon
this approach because of the small sample size.
Demographic and clinical characteristics
Most patients included in this study were white, single
men who were either unemployed or defined as being
long-term sick. The mean age of the participants was
40.86 years and they had been in contact with MH services
on average for almost 10 years. Demographic information





Days One year after PP
One year before PP initiation
Admissions/Bed days attributed to pre-PP Admissions/Bed days attributed to post-PP 





One year before PP One year after discharge  
Admissions/Bed days attributed to pre-PP Admissions/Bed days attributed to
post-PP 
Disregarded
Schematic representation of sensitivity analysis (inpatient initiated patients). PP, paliperidone palmitate.
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Number of admissions and bed days
The average number of admissions in the year before PP
initiation was 0.86, SD= 0.88, whereas the average
number of admissions in the year after PP initiation was
0.23, SD= 0.55; the median number of admissions
reduced from 1 to 0 over the study duration. The
Wilcoxon test (< 0.0001) and the Bootstrap paired sample
t-test [0.64, 95% confidence interval (CI): 0.42–0.85,
P= 0.001] showed a significant reduction in the number
of admissions after PP initiation.
There was a numerical decrease in the mean number of bed
days from 1 year before PP initiation (32.48; SD=44.76) to
1 year after PP initiation (31.22; SD=53.33). The median
number of bed days decreased from 20 to 0. The Wilcoxon
test (P=0.50) and the Bootstrap t-test (mean difference=
1.26, 95% CI: 10.66–13.95, P=0.84) showed a non-
significant difference in bed days between preinitiation and
postinitiation.
The histograms (Fig. 3) illustrate that, although many
patients had a reduction in bed days, some patients with
long admissions after PP initiation have skewed the mean.
These patients had long admissions for a number of reasons,
including disturbed behavior requiring intensive care, psy-
chiatric comorbidities, complex psychiatric needs, and pla-
cement issues. The distribution of pre–post differences in
the number of admissions and bed days was not significantly
different across both treatment settings and sexes.
Sensitivity analysis
Please see Table 2 for comparison of pre-PP and post-PP
differences according to the two different approaches
used to calculate before and after outcomes. The post-
hoc sensitivity analyses used the same analysis tests as
our primary approach and showed significant improve-
ments in average admissions from 0.86 to 0.23 and a
reduction in annual bed days from 26.77 before PP to
11.23 in the following year (Wilcoxon P= 0.003;
Bootstrap t-test= 15.55, 95% CI: 3.66–28.86; P= 0.016).
Discussion
Our primary endpoint analysis shows that the monthly
administration of long-acting injectable PP in 66 patients
with schizophrenia over 1 year was associated with a
significant reduction in the mean number of acute inpa-
tient admissions when compared with the previous year.
There was also a numerical (but nonsignificant) decrease
in the average number of bed days during the year fol-
lowing PP initiation. The median number of admissions
Table 1 Demographics of participants
Parameter at initiation of PP N=66
Age
Mean (SD) 40.86 (12.87)
Range 18–65
Duration of contact with services (N=63)










Care setting [n (%)]
Inpatient 36 (54.5)
Outpatient 30 (45.5)
Employment status [n (%)]
Employed 4 (6.1)
Unemployed 21 (31.8)
Long-term sick 23 (34.8)
Other 18 (27.2)





































































Histograms of bed days before and after PP. PP, paliperidone palmitate.
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reduced from 1 to 0 in the year after starting PP and the
median number of bed days decreased from 20 to 0 over
the same period. The primary strategy that we used in
order to calculate preoutcomes and postoutcomes is less
likely to favor the new drug compared with those studies
that discounted all index admission days from the post-
treatment group by inserting the mirror point at the
point of discharge (i.e. Taylor and Olofinjana, 2014), and
therefore our results could arguably present a realistic,
but more conservative, picture.
Because of a current lack of evidence from observational
naturalistic studies of PP it is difficult to compare and
contrast our results with previously published outcomes.
Direct comparisons of our findings with those of Taylor
and Olofinjana (2014) are also complicated by the dif-
fering clinical contexts, their larger sample size, inclusion
of noncontinuers of PP, and some of the demographic
characteristics of the participants. Despite the ethnicity
and percentage of women patients being very different in
our study compared with the study by Taylor and
Olofinjana (2014), there are some other demographics
that are very comparable: 45% of participants in each
study were initiated in outpatient settings, the mean
duration of illness in both studies was around 9 years, and
the average age was 41 years in our study (vs. 43 years).
Their primary analysis involved comparing the average
yearly rates/lengths of hospitalization during the 3 years
before PP initiation with the mean number of hospitali-
zations after PP, and for patients initiated as inpatients
this was calculated from the year after the point of dis-
charge from an index admission. This approach produced
significant reductions in the mean number of bed days
(38.78 to 23.09) and admissions (0.67 to 0.49) after start-
ing PP. However, using a mirror point inserted at the
time of initiation for all patents they found a significant
reduction in admissions of 0.67 to 0.51 and an increase in
the number of bed days from 38.78 to 56.75 – findings
that are less favorable to the results from our primary
endpoint analysis. Similarly to the study by Taylor and
Olofinjana (2014) the median number of admissions and
bed days in our study was 0 in the year after PP initiation
(irrespective of which method was used to calculate this).
When we adopted the same method of analysis as the
study by Taylor and Olofinjana (2014), our results show a
similar reduction in the number of bed days and a greater
reduction in the number of admissions for patients con-
tinuing PP for at least a year following initiation.
The findings resulting from our sensitivity analysis
highlight how the varying mirror points used to calculate
before and after outcomes can have a large influence on
results. Our post-hoc analysis is certainly more likely to
favor the new drug as it discounts all index admission bed
days from the post-PP calculations; as could be expected,
this shows large and significant reductions in hospitali-
zations in the year following PP. A number of other
researchers (i.e. Faries et al., 2009; Taylor and Olofinjana,
2014) have also demonstrated that the different strategies
used in mirror-image studies to handle acute-service use
occurring just after an antipsychotic medication change
can have profound effects on study findings. Strategies
that compare the number of bed days in the year before
initiation with the number in the year after patients are
discharged from the index admission tend to favor the
new drug, whereas approaches that attribute bed days
from an index admission to post-treatment immediately
after initiation are likely to underestimate the positive
effects of the new antipsychotic (Faries et al., 2009;
Taylor and Olofinjana, 2014). Therefore, using a mirror
point of 2 weeks after initiation seemed an appropriate
way for us to address these issues and minimize the risk
of overestimating or underestimating the effects of PP on
hospitalizations.
Given the relatively expensive cost of PP it is worth
considering its potential cost effectiveness in our study
population. A widely used and broadly illustrative method
for estimating cost effectiveness is the calculation of
savings made on reduced hospitalizations and offsetting
these against the costs of medication (Bernardo, et al.,
2006), but as our sensitivity analysis shows, in this study,
the results will vary based on the approach used to mea-
sure before and after effects.
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(i) Mirror point inserted at 14 days after PP initiation for all patients (Fig. 1).
(ii) Mirror point inserted at PP initiation for all patients and index admission bed days after PP disregarded for patients initiated while in hospital (Fig. 2).
CI, confidence interval; PP, paliperidone palmitate.
*Significant at P<0.05.
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The average monthly maintenance dose of PP in this
study is 102 mg (excluding any additional amounts for
the initial loading dose) and therefore the conservative
annual purchase cost per patient is around £3769. Given
that the Trust’s average acute admission length is
31.4 days, and one acute bed day in our Trust costs £375,
this equates to an average cost of £11 775 per admission.
As the bootstrap t-test results in our primary endpoint
analysis show a significant reduction of 0.64 admissions
per patient in the year following PP, this suggests an
average saving of £7536, which clearly outweighs the
annual PP cost of £3769. Our sensitivity analysis (which is
arguably more likely to favor PP) additionally demon-
strates a significant reduction of 15.55 bed days after
initiation and this equates to a potential acute hospitali-
zation cost saving of £2062 per patient initiated on PP
(£5831–£3769). These (albeit somewhat crude) calcula-
tions suggest that PP is largely cost effective in our
clinical setting.
Because of the limitations of the retrospective observa-
tional study design and the relatively small sample size,
our results should be treated with caution, particularly as
any changes in rates and lengths of admissions may be
due to numerous possible extraneous influences. We
cannot establish with certainty that PP reduces the
number of acute inpatient admissions or is more/less
superior to other medications because this is an uncon-
trolled study without a comparison group. As we did not
include a control arm in our study the changes in the
number of bed days and admission rates observed may be
a reflection of background variations occurring irrespec-
tive of treatment. We were also not able to access infor-
mation about which drugs patients were prescribed
before initiation, and therefore we are not able to identify
any potential associations between these and differences
in rates of hospitalization.
All data originated from patients who were adherent with
their prescribed PP treatment over at least a year, and as a
result our findings will be more positive than those stu-
dies that included data from patients who had dis-
continued treatment. In addition, patients were not
randomized to receive treatment, and therefore decisions
about which patients were selected by prescribers to start
PP is likely to have been based on their perceived
increased likelihood of who would respond to the drug.
Similarly, local prescribing guidelines suggest that only
patients who have had an adequate previous response to
oral risperidone, which is almost identical to PP in its
pharmacological properties (Spina and Cavallaro, 2007;
Bishara and Taylor, 2008), can be considered for PP; this
may have resulted in patients who respond to, but are
nonadherent with oral risperidone, starting PP, and
therefore the patients included in this study are likely to
represent the most responsive population.
Despite these limitations, our findings are based on
routinely collected clinical data in a real-world setting.
We have not excluded any patients with substance mis-
use or physical/MH comorbidities; there were no major
changes in hospital admission policy or bed closures that
are likely to have affected the rates of hospitalization, and
therefore the results may plausibly reflect the naturalistic
outcomes of patients with schizophrenia who continue
PP treatment within the MH trust studied.
In conclusion, this observational study suggests that PP
initiation in patients with a diagnosis of schizophrenia
(and who continue with regular monthly injections over
12 months) is likely to be associated with a significant
reduction in the number of hospital admissions when
compared with the previous year.
Acknowledgements
This study was funded by unrestricted investigator-
initiated grant from Janssen UK.
Conflicts of interest
D.B. has received research funding from Janssen and
Pfizer, and has received honorarium payments for con-
sultancy from Lundbeck, BMS, and Janssen. J.S. has
received research funding from Janssen and honoraria for
consultancy work from Janssen, Lundbeck, Astra-
Zeneca, Sunovion, BMS, and Lilly. For the remaining
authors there are no conflicts of interest.
References
Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D (2013). Paliperidone pal-
mitate long‐acting injection – prospective year‐long follow‐up of use in clinical
practice. Acta Psychiatr Scand 130:46–51. DOI: 10.1111/acps.12201.
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW (2006).
Medication adherence and long-term functional outcomes in the treatment of
schizophrenia in usual care. J Clin Psychiatry 67:453–460.
Bernardo M, Ramón Azanza J, Rubio-Terrés C, Rejas J (2006). Cost-effectiveness
analysis of schizophrenia relapse prevention : an economic evaluation of the
ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. Clin
Drug Investig 26:447–457.
Bishara D, Taylor D (2008). Upcoming agents for the treatment of schizophrenia:
mechanism of action, efficacy and tolerability. Drugs 68:2269–2292.
Byerly MJ, Nakonezny PA, Lescouflair E (2007). Antipsychotic medication
adherence in schizophrenia. Psychiatr Clin North Am 30:437–452.
Chue P, Llorca P, Duchesne I, Leal A, Rosillon D, Mehnert A (2005).
Hospitalization rates in patients during long-term treatment with long-acting
risperidone injection. J Appl Res Clin Exp Ther 5:266.
Edwards NC, Locklear JC, Rupnow MF, Diamond RJ (2005). Cost effectiveness
of long-acting risperidone injection versus alternative antipsychotic agents in
patients with schizophrenia in the USA. Pharmacoeconomics 23:75–89.
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006).
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines
for biological treatment of schizophrenia, part 2: long-term treatment of
schizophrenia. World J Biol Psychiatry 7:5–40.
Faries DE, Nyhuis AW, Ascher-Svanum H (2009). Methodological issues in
assessing changes in costs pre- and post-medication switch: a schizophrenia
study example. Cost Eff Resour Alloc 7:11.
Glick ID, Bossie CA, Alphs L, Canuso CM (2009). Onset and persistence
of antipsychotic response in patients with schizophrenia. J Clin Psycho-
pharmacol 29:pp. 542–547.
Haddad PM, Taylor M, Niaz OS (2009). First-generation antipsychotic long-acting
injections v. oral antipsychotics in schizophrenia: systematic review of ran-
domised controlled trials and observational studies. Br J Psychiatry Suppl
52:S20–S28.
Paliperidone acute hospitalization rates Bressington et al. 235
IBM Corp. (2012). IBM SPSS Statistics for Windows, version 210. Armonk, NY:
IBM Corp.
Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. (1992).
Schizophrenia: manifestations, incidence and course in different cultures.
A World Health Organization ten-country study. Psychol Med Monogr Suppl
20:1–97.
Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset
hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and
extended. Biol Psychiatry 57:1543–1549.
Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L (2010). A pro-
spective study comparing the long-term effectiveness of injectable risperidone
long-acting therapy and oral aripiprazole in patients with schizophrenia.
Psychiatry (Edgmont) 7:23–31.
Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al.,
e-STAR Spanish Study Group (2009). Long-term outcomes in patients with
schizophrenia treated with risperidone long-acting injection or oral anti-
psychotics in Spain: results from the electronic Schizophrenia Treatment
Adherence Registry (e-STAR). Eur Psychiatry 24:287–296.
Olivares JM, Sermon J, Hemels M, Schreiner A (2013). Definitions and drivers of
relapse in patients with schizophrenia: a systematic literature review. Ann Gen
Psychiatry 12:32.
Polsky D, Doshi JA, Bauer MS, Glick HA (2006). Clinical trial-based cost-
effectiveness analyses of antipsychotic use. Am J Psychiatry 163:
2047–2056.
Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Liang MH
(2011). Long-acting risperidone and oral antipsychotics in unstable schizo-
phrenia. N Engl J Med 364:842–851.
Sheehan JJ, Reilly KR, Fu DJ, Alphs L (2012). Comparison of the peak-to-trough
fluctuation in plasma concentration of long-acting injectable antipsychotics
and their oral equivalents. Innov Clin Neurosci 9:17–23.
Spina E, Cavallaro R (2007). The pharmacology and safety of paliperidone
extended-release in the treatment of schizophrenia. Expert Opin Drug Saf
6:651–662.
Taylor D, Cornelius V (2010). Risperidone long-acting injection: factors associated
with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up.
J Psychopharmacol 24:995–999.
Taylor D, Olofinjana O (2014). Long-acting paliperidone palmitate–interim results
of an observational study of its effect on hospitalization. Int Clin
Psychopharmacol 29:229–234.
Taylor M, Currie A, Lloyd K, Price M, Peperell K (2008). Impact of risperidone long
acting injection on resource utilization in psychiatric secondary care.
J Psychopharmacol 22:128–131.
Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A (1998). Health of
the Nation Outcome Scales (HoNOS). Research and development. Br J
Psychiatry 172:11–18.
Young CL, Taylor DM (2006). Health resource utilization associated with switching
to risperidone long-acting injection. Acta Psychiatr Scand 114:14–20.
236 International Clinical Psychopharmacology 2015, Vol 30 No 4
